These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 29511948)
1. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. Breccia M; Foà R Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948 [TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694 [No Abstract] [Full Text] [Related]
3. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Cortes J; Rea D; Lipton JH Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563 [TBL] [Abstract][Full Text] [Related]
4. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Shih YT; Cortes JE; Kantarjian HM Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943 [TBL] [Abstract][Full Text] [Related]
6. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia. Caldemeyer L; Akard LP Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641 [TBL] [Abstract][Full Text] [Related]
7. Discontinuation of TKI therapy and 'functional' cure for CML. Mahon FX Best Pract Res Clin Haematol; 2016 Sep; 29(3):308-313. PubMed ID: 27839571 [TBL] [Abstract][Full Text] [Related]
8. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527 [TBL] [Abstract][Full Text] [Related]
9. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety. Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M Expert Opin Drug Saf; 2024 Aug; 23(8):969-979. PubMed ID: 38873693 [TBL] [Abstract][Full Text] [Related]
10. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Dulucq S; Mahon FX Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039 [TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia. Elsayed AG; Srivastava R; Jamil MO Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389 [TBL] [Abstract][Full Text] [Related]
12. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101 [TBL] [Abstract][Full Text] [Related]
13. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world]. Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147 [No Abstract] [Full Text] [Related]
14. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108 [TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives]. Kumagai T Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514 [TBL] [Abstract][Full Text] [Related]
16. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon. Elias F; Gebran A; Said C; Beker RV; Ammar W J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826 [TBL] [Abstract][Full Text] [Related]